The practice of evaluating life insurance applicants through medical examinations and questionnaires often extends to substance use. These evaluations aim to assess an individual’s overall health and risk profile. The presence of tetrahydrocannabinol (THC), the psychoactive compound in cannabis, can be detected through various testing methods, including urine, blood, and hair follicle analysis. These tests identify the presence of THC metabolites, indicating recent cannabis consumption.
Life insurance companies utilize risk assessment to determine premiums and coverage eligibility. Historically, any form of substance use, including cannabis, was viewed as an increased risk factor. This perception stemmed from associations with potential health complications and lifestyle choices linked to higher mortality rates. The increased availability and changing legal landscape surrounding cannabis have prompted insurers to re-evaluate their policies regarding cannabis use. However, the impact of cannabis use on mortality rates remains a subject of ongoing research, influencing how insurance companies adjust their underwriting processes.